Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom
Table 8
Random effects estimates of the probabilities of grade 3–5 AEs for each comparator based on Freeman-Tukey transformation (%)a.
Description of adverse event (% [SE])
Pazopanib
BSC
Trabectedin
Ifosfamide 3 g/m2
GEM/DOC
General
Alopecia
0.1 (6.4)
0.2 (9.0)
0.5 (13.5)
64.6 (15.6)
0.5 (14.3)
Asthenia/fatigue
13.9 (6.4)
5.2 (9.0)
6.9 (15.5)
5.2 (9.0)
3.0 (14.3)
Hypertension
6.8 (6.4)
0.2 (9.0)
0.2 (9.0)
0.2 (9.0)
0.2 (9.0)
Myalgia/muscle pain
2.3 (6.4)
0.2 (9.0)
0.2 (9.0)
0.2 (9.0)
0.2 (9.0)
Neurotoxicity/peripheral sensory neuropathy
0.6 (6.4)
1.2 (9.0)
1.2 (9.0)
6.0 (15.6)
0.5 (14.3)
Edema
2.3 (6.4)
2.0 (9.0)
4.1 (16.7)
2.0 (9.0)
19.4 (14.3)
Liver toxicity
ALT elevation
9.9 (6.5)
3.6 (9.0)
43.2 (12.5)
1.2 (9.0)
1.2 (9.0)
AST elevation
8.2 (6.5)
2.0 (9.0)
35.3 (8.2)
1.2 (9.0)
0.5 (14.3)
Cardiovascular
Cardiac toxicity
0.1 (6.4)
0.2 (9.0)
0.2 (9.0)
0.2 (9.0)
0.2 (9.0)
Left ventricular dysfunction
1.9 (6.4)
0.2 (9.0)
0.2 (9.0)
0.2 (9.0)
0.2 (9.0)
Pulmonary
Dyspnea
6.4 (6.4)
6.0 (9.0)
4.2 (8.7)
6.0 (9.0)
0.5 (14.3)
Pleural effusion
2.3 (6.4)
0.2 (9.0)
0.2 (8.7)
0.2 (9.0)
0.5 (14.3)
Pneumothorax
2.3 (6.4)
0.2 (9.0)
0.2 (9.0)
0.2 (9.0)
0.2 (9.0)
Pulmonary toxicity
0.1 (6.4)
0.2 (9.0)
0.2 (9.0)
0.2 (9.0)
9.2 (14.3)
Gastrointestinal
Decreased appetite/anorexia
6.0 (6.4)
0.2 (9.0)
1.5 (7.3)
0.2 (9.0)
0.2 (9.0)
Diarrhea
4.8 (6.4)
1.2 (9.0)
0.9 (7.3)
1.2 (9.0)
1.2 (9.0)
Nausea/vomiting
6.8 (6.4)
2.8 (9.0)
13.5 (5.6)
18.3 (15.6)
3.0 (14.3)
Weight decreased
3.9 (6.4)
0.2 (9.0)
0.2 (9.0)
0.2 (9.0)
0.2 (9.0)
Hematologic abnormalities
Febrile neutropenia
0.1 (6.4)
0.2 (9.0)
5.3 (14.5)
0.2 (9.0)
0.2 (9.0)
Anemia/hemoglobin
6.4 (6.4)
2.0 (9.0)
13.6 (9.9)
20.7 (15.6)
25.5 (14.3)
Leucopenia
1.4 (6.4)
0.2 (9.0)
43.2 (7.2)
64.6 (15.6)
23.5 (14.3)
Neutropenia/neutrophils
4.4 (6.4)
0.2 (9.0)
49.2 (8.7)
50.0 (15.6)
21.4 (14.3)
Thrombocytopenia/low platelets
3.9 (6.4)
0.2 (9.0)
15.7 (5.6)
15.8 (15.6)
39.8 (14.3)
AE: adverse event; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BSC: best supportive care; GEM/DOC: gemcitabine + docetaxel; SE: standard error. SE on Freeman-Tukey transformation scale. Note: if there is no information on AE then probability [SE] is assumed to be the same as placebo in PALETTE.
